FDA approves first biosimilar for certain breast, stomach cancers


fda breast stomach cancer

On Dec. 1, the U.S. Food and Drug Administration (FDA) approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+). This is the first biosimilar approved in the U.S. for the treatment of breast or stomach cancer. 

Read more via Fda.gov.


Please enter your comment!
Please enter your name here